Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
|Articles|October 25, 2011
Gateway 2011: Sensient Pharmaceutical Coating Systems
Advertisement
Sensient® Pharmaceutical Coating Systems is a global leader in superior coating systems, brand-defining color solutions, and enhanced product performance for the pharmaceutical and nutraceutical markets. A single source for complete coating and visual enhancement solutions, we’re committed to innovation not only in our superior products and solutions but also in our personalized, responsive service.
Sensient Pharmaceutical Coating Systems leads the industry in the development and manufacture of innovative coatings and colors for the pharmaceutical and nutraceutical industries. Our coatings, excipients, and imprint inks offer visual and functional attributes necessary for brand definition, product identification, and trademark protection. Please visit us at AAPS 2011 at Booth #1419.
Sensient Pharmaceutical Coating Systems
2515 N. Jefferson, St. Louis, MO 63106
Phone: 800.325.8110
E-mail:
URL:
Advertisement
Related to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5